Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the efficacy and safety of Human Insulin Inhalation Powder [also known as
AIR® Inhaled Insulin][AIR® is a registered trademark of Alkermes,Inc.] in patients with Type
2 diabetes who are currently being treated with once daily insulin glargine injections. The
present study is intended to determine if mealtime AIR® Insulin may be superior to once-daily
insulin glargine injections.